Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. The company is headquartered in Pearl River, New York and currently employs 102 full-time employees. The company went IPO on 2006-02-10. The firm markets Inbrija (levodopa inhalation powder), which is approved in the United States for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson’s disease treated with carbidopa/levodopa. Inbrija is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor, such as phenelzine or tranylcypromine within the last two weeks. Inbrija utilizes its ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. ARCUS is a dry-powder pulmonary drug delivery technology. The company also markets the branded AMPYRA (dalfampridine) extended-release tablets, 10 mg, to improve walking in adults with multiple sclerosis. Ampyra is marketed as Fampyra outside the United States by Biogen International GmbH.

Industry: Biological Products, (No Diagnostic Substances) Peers: Aditxt Inc Benitec Biopharma Inc Panbela Therapeutics, Inc. Statera Biopharma, Inc. CONTRAFECT Corp Xenetic Biosciences Inc NAVIDEA BIOPHARMACEUTICALS, INC. Phio Pharmaceuticals Corp Dogwood Therapeutics Inc